Jupiter Neurosciences Inc
JUNS
查看详细走势图
1.100USD
-0.020-1.79%
收盘 12/19, 16:00（美东）报价延迟15分钟
37.72M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.79%
5天
-1.79%
1月
-10.57%
6月
-0.90%
今年开始到现在
-89.72%
1年
-88.69%
查看详细走势图
TradingKey Jupiter Neurosciences Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Jupiter Neurosciences Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名148/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价0.00。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Jupiter Neurosciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Jupiter Neurosciences Inc亮点
亮点风险
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Jupiter Neurosciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Jupiter Neurosciences Inc简介
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
公司代码JUNS
公司Jupiter Neurosciences Inc
CEORosen (Christer)
网址https://jupiterneurosciences.com/
常见问题
Jupiter Neurosciences Inc(JUNS)的当前股价是多少？
Jupiter Neurosciences Inc(JUNS)的当前股价是 1.100。
Jupiter Neurosciences Inc的股票代码是什么？
Jupiter Neurosciences Inc的股票代码是JUNS。
Jupiter Neurosciences Inc股票的52周最高点是多少？
Jupiter Neurosciences Inc股票的52周最高点是--。
Jupiter Neurosciences Inc股票的52周最低点是多少？
Jupiter Neurosciences Inc股票的52周最低点是--。
Jupiter Neurosciences Inc的市值是多少？
Jupiter Neurosciences Inc的市值是37.72M。
Jupiter Neurosciences Inc的净利润是多少？
Jupiter Neurosciences Inc的净利润为-2.44M。
现在Jupiter Neurosciences Inc(JUNS)的股票是买入、持有还是卖出？
根据分析师评级，Jupiter Neurosciences Inc(JUNS)的总体评级为买入，目标价格为--。
Jupiter Neurosciences Inc(JUNS)股票的每股收益（EPS TTM）是多少
Jupiter Neurosciences Inc(JUNS)股票的每股收益（EPS TTM）是-0.233。
相关品种
